This report evaluates the analytical validity, clinical validity, and clinical utility of the ChemoFx test, an in vitro patient tumor–derived cell culture assay that determines how cancer cells may respond to chemotherapeutic agents in order to help guide physicians’ treatment decisions in patients with gynecologic cancer.
Precision Medicine
The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
- Will testing change patient management for this indication?
- If so, what tests and/or therapies should I use?
- Should we cover testing and/or therapies?
- Can we manage these services internally?
- Precision Medicine Insights
- Precision Medicine Research Briefs
Breast Cancer Index (BioTheranostics Inc.) for Lymph Node–Negative Patients
This report evaluates the analytical validity, clinical validity, and clinical utility of the Breast Cancer Index test (BioTheranostics Inc.) for lymph node–negative patients.
Breast Cancer Index (BioTheranostics Inc.) for Lymph Node–Positive (1-3) Patients
This report evaluates the analytical validity, clinical validity, and clinical utility of the Breast Cancer Index test (BioTheranostics Inc.) for lymph node–positive (1-3) patients.
Epi proColon (Epigenomics Inc.)
Focus of the Report: This report evaluates the analytical validity, clinical validity, and clinical utility of the Food and Drug Administration–approved Epi proColon blood-based liquid biopsy test, for the detection of methylated Septin 9 (SEPT9) as cell-free circulating DNA, that is intended to screen for colorectal cancer (CRC) in average-ris…
Genetic Testing for Monogenic Systemic Autoinflammatory Disorders (SAIDs)
Focus of Report: This report reviews clinical study abstracts and clinical practice guidelines addressing genetic testing for monogenic systemic autoinflammatory disorders (SAIDs). Autoinflammatory disorders that result from polygenic or multifactorial causes are not included in this report.
At least 38 separate monogeni…
Expanded Carrier Screening
Focus of Report: This report reviews clinical study abstracts and clinical practice guidelines addressing expanded carrier screening.
FirstSightCRC (CellMax Life)
The report evaluates the analytical validity, clinical validity, and clinical utility of the FirstSightCRC test, a liquid biopsy test that detects and analyzes circulating tumor cells (CTCs) and is intended to predict the likelihood of having precancerous adenomatous polyps or colorectal cancer (CRC) in patients eligible for CRC screening.
DecisionDx-UM (Castle Biosciences Inc.)
This report evaluates the analytical validity, clinical validity, and clinical utility of the DecisionDx-UM test.
Prenatal Whole Genome Sequencing and Prenatal Whole Exome Sequencing
This report evaluates the clinical utility of prenatal whole genome sequencing and prenatal whole exome sequencing to improve diagnosis and inform pregnancy and post-pregnancy patient management where fetal abnormalities have been detected by ultrasound or other testing.
ColonSentry (Stage Zero Life Sciences)
The report evaluates the analytical validity, clinical validity, and clinical utility of the ColonSentry liquid biopsy test, a gene expression assay intended to estimate the current relative risk of having colorectal cancer (CRC) for patients eligible for CRC screening.